Clinical Trials · NCT07313761

A Trial to Compare the Extent to Which Maridebart Cafraglutide (AMG 133) is Made Available in the Body When Administered Using Two Subcutaneous Presentations

Name: A Trial to Compare the Extent to Which Maridebart Cafraglutide (AMG 133) is Made Available in the Body When Administered Using Two Subcutaneous Presentations
Creator: Peptide Science Daily
License: https://clinicaltrials.gov/about-site/terms-conditions

CompletedPhase 1Maridebart cafraglutide

Phase: Phase 1
Recruitment status: Completed
Sponsor: Amgen
Enrollment: 349
Start date: Dec 2025
Locations: 4 sites, United States
Primary endpoint: Area Under the Plasma Concentration-time Curve (AUC) From Time 0 to Infinity (AUCinf) of AMG 133

View Maridebart-Cafraglutide compound reference